Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly, EVA Pharma Announce Regulatory Approval for Locally Manufactured Insulin
Details : Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.
Product Name : Humalog
Product Type : Peptide
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lilly, EVA Pharma Collaborate To Expand Baricitinib Access in Low-Income Nations
Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 09, 2024
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Alpha Lipoic Acid
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : Ain Shams University
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Lipoic Acid in Pediatrics on Hemodialysis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Alpha Lipoic Acid
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : Ain Shams University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally
Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.
Product Name : Sunlenca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Alpha Lipoic Acid
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : MARC-CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : Alpha Lipoic Acid
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : MARC-CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gleptomet
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 05, 2023
Lead Product(s) : Gleptomet
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nirmatrelvir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Nirmatrelvir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Egyvax Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 01, 2022
Lead Product(s) : Egyvax Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Recipient : Alexandria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Anti-diabetic Drugs and Fatty Liver Management
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2021
Lead Product(s) : Metformin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Recipient : Alexandria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Revemact
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 22, 2021
Lead Product(s) : Revemact
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable